论文部分内容阅读
目的观察雷贝拉唑肠溶胶囊口服联合马来酸曲美布汀对胃食管返流性咳嗽的临床疗效。方法 75例符合入选标准的胃食管返流性咳嗽患者,根据就诊日期随机分成观察组39例和对照组36例。对照组服用雷贝拉唑肠溶胶囊20 mg,1次/d,以日间咳嗽为主(包括日夜无差异的)的患者晨起服,以夜间咳嗽为主的患者睡前服;观察组在对照组用药的基础上加用马来酸曲美布汀分散片0.2 g,3次/d餐前口服;疗程均为12周。结果治疗后观察组和对照组咳嗽和胃食管反流症状的评分均较治疗前明显下降(P<0.05),观察组降低值分别为(1.303±0.126)和(6.106±0.230),对照组降低值分别为(0.707±0.263)和(3.322±0.161),组间比较以联合用药疗效为佳(P<0.05)。结论雷贝拉唑肠溶胶囊口服联合马来酸曲美布汀治疗胃食管返流性咳嗽有较好疗效,联合用药优于单用雷贝拉唑肠溶胶囊。
Objective To observe the clinical efficacy of rabeprazole enteric-coated capsules combined with trimebutine maleate on gastroesophageal reflux cough. Methods Seventy-five patients with gastroesophageal reflux cough who met the inclusion criteria were randomly divided into observation group (39 cases) and control group (36 cases). Control group taking rabeprazole enteric-coated capsules 20 mg, 1 time / d, mainly in daytime cough (including day and night no difference) patients morning service, nighttime cough-based patients before going to bed; observation group In the control group on the basis of medication plus trimebutine maleate tablets 0.2 g, 3 times / d oral pre-meal; treatment were 12 weeks. Results After treatment, the cough and gastroesophageal reflux symptom scores of the observation group and the control group were significantly lower than those before treatment (P <0.05), and the reduction values of the observation group were (1.303 ± 0.126) and (6.106 ± 0.230) (0.707 ± 0.263) and (3.322 ± 0.161) respectively. The efficacy of combination therapy was better than that of combination therapy (P <0.05). Conclusion Rabeprazole enteric-coated capsules combined with trimebutine maleate in the treatment of gastroesophageal reflux cough have a better curative effect, and the combination is superior to rabeprazole enteric-coated capsules alone.